Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. operates as a biopharmaceutical company engaged in developing and commercializing novel medicines for patients living with rare diseases. It offers Firdapse for the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of Duchenne muscular dystrophy. Catalyst Pharmaceuticals, Inc. was formerly known as Catalyst Pharmaceutical Partners Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. The company was founded in 2002 and is based in Coral Gables, Florida. As of July 15, 2026, Catalyst Pharmaceuticals, Inc. operates as a subsidiary of Angelini Pharma S.p.a.